SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                   FORM 10-QSB

                                   (Mark One)

              [X] Quarterly report under Section 13 or 15(d) of the
                        Securities Exchange Act of 1934

                 FOR THE QUARTERLY PERIOD ENDED: March 31, 2006

       [ ] Transition report under Section 13 or 15(d) of the Exchange Act

             For the transition period from __________ to __________

                         Commission file number 0-50977

                          ASIA BIOTECHNOLOGY GROUP INC.
        (Exact Name of Small Business Issuer as Specified in Its Charter)

          DELAWARE                                                   N/A
(State or Other Jurisdiction of                                 (IRS Employer
Incorporation or Organization)                               Identification No.)

                  No.7 Bohaisanlu, Pingfang Industrial District
              Economic and Technological Development Area, Harbin,
                    Heilongjiang Province, P.R. China 150069
                    (Address of Principal Executive Offices)

                                 +86 451 8681288
                              +86 451 8681399(Fax)
                (Issuer's Telephone Number, Including Area Code)

                            Echelon Acquisition Corp.
                 492 Andrew Avenue, Encinitas, California 92024
              (Former Name, Former Address and Former Fiscal Year,
                          If changed since Last Report)

Check whether the issuer:  (1) filed all reports required to be filed by Section
13 or 15(d) of the  Exchange  Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports),  and (2) has been
subject to such filing requirements for the past 90 days. Yes [X] No [ ]

State the number of shares outstanding of each of the issuer's classes of common
equity,  as of the latest  practicable  date:  58,240,000 shares of common stock
issued and outstanding as of September 30, 2006.

Transitional Small Business Disclosure Format (Check one): Yes [ ] No [X]

<PAGE>

                                TABLE OF CONTENTS

Part I  Financial Information ...............................................F-1
Item 1. Financial Statements.................................................F-1
Item 2 Management's Discussion and Analysis of
         Financial Condition and Results of Operation..........................1
Item3.Controls and Procedures..................................................6
Part II  Other Information.....................................................6
Item 1. Legal Proceedings......................................................6
Item 2 Changes in Securities...................................................7
Item 3 Defaults upon Senior Securities ........................................7
Item 4 Submission of Matters to a Vote of Security Holders.....................7
Item 5 Other Information.......................................................7
Item 6 Exhibits................................................................7




















<PAGE>

                         PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

                          ASIA BIOTECHNOLOGY GROUP INC.
                          (A DEVELOPMENT STAGE COMPANY)

                                 BALANCE SHEETS


                                                         March 31,    March 31,
                                                           2006         2005
                                                         ---------    ---------
                                                         Unaudited    Unaudited
ASSETS

Current assets:
  Cash and cash equivalents                              $    --      $    --
                                                         ---------    ---------
               Total assets                              $    --      $    --
                                                         =========    =========

LIABILITIES AND SHAREHOLDERS' DEFICIT

Current liabilities:
  Accrued liabilities                                    $   3,300    $     800
                                                         ---------    ---------
               Total current liabilities                     3,300          800
                                                         ---------    ---------

               Total liabilities                             3,300          800


Shareholders' deficit:
 Preferred  Stock at $0.001 par value; authorized             --           --
20,000,000 shares; no shares issued and outstanding
Common stock at $0.001 par value; authorized                11,648       11,648
 100,000,000 shares; 11,648,000 shares issued
 and outstanding
Deficit accumulated during the development stage           (14,948)     (12,448)
                                                         ---------    ---------
               Total shareholders' deficit                  (3,300)        (800)
                                                         ---------    ---------
               Total liabilities and shareholders'       $    --      $    --
                                                         =========    =========




See accompanying notes to financial statements.


                                      F-1
<PAGE>
<TABLE>
<CAPTION>

                          ASIA BIOTECHNOLOGY GROUP INC.
                          (A DEVELOPMENT STAGE COMPANY)

                            STATEMENTS OF OPERATIONS


                                                                                    Period from
                                               For the three     For the three     July 27, 2004
                                                months ended      months ended     (inception) to
                                                  March 31,         March 31,         March 31,
                                                    2006              2005              2006
                                               --------------    --------------    --------------
<S>                                            <C>               <C>               <C>
                                                 Unaudited         Unaudited         Unaudited

Revenue                                        $         --      $         --      $         --

General and administrative
  Organization and related expenses                      --                --                 148
  General and administrative expenses                   2,500            11,500            14,800
                                               --------------    --------------    --------------
    Total general and administrative                    2,500            11,500            14,948
                                               --------------    --------------    --------------

Net loss                                               (2,500)   $      (11,500)   $      (14,948)
                                               ==============    ==============    ==============

Net loss per share
- basic and fully diluted                      $        (0.00)   $        (0.00)   $        (0.00)
                                               ==============    ==============    ==============

Weighted average ordinary shares outstanding
- basic and fully diluted                          11,648,000        11,648,000        11,648,000
                                               ==============    ==============    ==============
</TABLE>










See accompanying notes to financial statements.


                                      F-2
<PAGE>
<TABLE>
<CAPTION>

                          ASIA BIOTECHNOLOGY GROUP INC.
                          (A DEVELOPMENT STAGE COMPANY)

                            STATEMENTS OF CASH FLOWS


                                                                                            Period from
                                                       For the three     For the three     July 27, 2004
                                                        months ended      months ended     (inception) to
                                                          March 31,         March 31,         March 31,
                                                            2006              2005              2006
                                                       --------------    --------------    --------------
<S>                                                    <C>               <C>               <C>
                                                         Unaudited         Unaudited         Unaudited
Cash flows from operating activities
  Net loss                                             $       (2,500)   $      (11,500)   $      (14,948)

  Issuance of stock for services rendered                        --              11,500            11,648
  Increase in accrued liabilities                               2,500              --               3,300
                                                       --------------    --------------    --------------
Net cash generated from operating activities                     --                --                --

Cash flows from investing activities                             --                --                --

Cash flows from financing activities                             --                --                --
                                                       --------------    --------------    --------------

Net increase (decrease) in cash and cash equivalents             --                --                --
Cash and cash equivalents, beginning of year                     --                --                --
                                                       --------------    --------------    --------------
Cash and cash equivalents, end of year                 $         --      $         --      $         --
                                                       ==============    ==============    ==============

Supplementary disclosures of cash flow information:
  Cash paid (refund) during the year for:
    Interest                                           $         --      $         --      $         --
    Income taxes                                       $         --      $         --      $         --
</TABLE>








See accompanying notes to financial statements.


                                      F-3
<PAGE>

NOTE 1  BUSINESS DESCRIPTION AND ORGANIZATION

     Asia  Biotechnology  Group Inc. (the  "Company") was formerly named Echelon
Acquisition Corp. which was incorporated under the laws of the State of Delaware
on July 27, 2004 and has been inactive since  inception.  The Company intends to
serve as a vehicle to effect an asset acquisition,  merger,  exchange of capital
stock or other business combination with a domestic or foreign business.

NOTE 2  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation - Development Stage Company

     The Company has not earned any revenue from  operations.  Accordingly,  the
Company's  activities  have been accounted for as those of a "Development  Stage
Enterprise"  as set forth in Statement of Financial  Accounting  Standards No. 7
("SFAS 7").  Among the  disclosures  required  by SFAS 7 are that the  Company's
financial  statements be identified as those of a development stage company, and
that the statements of operations,  stockholders' equity and cash flows disclose
activity since the date of the Company's inception.

A.   Accounting Method

     The Company's financial statements are prepared using the accrual method of
accounting. The Company has elected a fiscal year ending on December 31.

B.   Cash and cash equivalents

     Cash and cash  equivalents  include cash on hand,  cash accounts,  interest
bearing  savings  accounts and time  certificates  of deposit with a maturity of
three months or less when purchased.

C.   Foreign currency translation

     Transactions  and  balances  originally  denominated  in U.S.  dollars  are
presented  at  their  original  amounts.  Transactions  and  balances  in  other
currencies  are  converted  into U.S.  dollars in accordance  with  Statement of
Financial  Accounting  Standards (SFAS) No. 52, "Foreign Currency  Translation,"
and are included in determining net income or loss.

     For foreign operations with the local currency as the functional  currency,
assets  and  liabilities  are  translated  from the local  currencies  into U.S.
dollars at the exchange rate  prevailing  at the balance  sheet date.  Revenues,
expenses  and cash flows are  translated  at the average  exchange  rate for the
period to approximate  translation at the exchange rate  prevailing at the dates
those  elements  are  recognized  in  the  financial   statements.   Translation


                                      F-4
<PAGE>

adjustments  resulting  from the  process  of  translating  the  local  currency
financial statements into U.S. dollars are included in determining comprehensive
loss.

D.   Use of estimates

     The  preparation  of financial  statements  in  conformity  with  generally
accepted  accounting  principles  requires  management  to  make  estimates  and
assumptions  that  affect the  reported  amounts of assets and  liabilities  and
disclosures  of contingent  assets and  liabilities at the date of the financial
statements  and the  reported  amounts  of  revenues  and  expenses  during  the
reporting period. Actual results could differ from those estimates.

E.   Significant Estimates

     Several areas require management's  estimates relating to uncertainties for
which it is reasonably possible that there will be a material change in the near
term.  The more  significant  areas  requiring the use of  management  estimates
relate to valuation of the useful lives of the Company's equipment and valuation
of contingent liabilities and the valuation of stock issued for services.

F.   Income Taxes

     The Company  accounts  for income  taxes under the  Statement  of Financial
Accounting  Standards ("SFAS") Statement No. 109,  "Accounting for Income Taxes"
"Statement  109".  Under Statement 109,  deferred tax assets and liabilities are
recognized for the future tax consequences  attributable to differences  between
the financial  statement carrying amounts of existing assets and liabilities and
their  respective tax basis.  Deferred tax assets and  liabilities  are measured
using  enacted  tax rates  expected  to apply to taxable  income in the years in
which those temporary differences are expected to be recovered or settled. Under
Statement 109, the effect on deferred tax assets and  liabilities of a change in
tax rates is  recognized  in income in the period that  includes  the  enactment
date.  There were no current or deferred  income tax expense or benefits  due to
the Company not having any  material  operations  for the period ended March 31,
2006

G.   Basic Loss Per Common Share

     Basic  loss per  common  share has been  calculated  based on the  weighted
average number of shares  outstanding during the period after giving retroactive
effect to stock splits.  There are no dilutive  securities at March 31, 2006 for
purposes of computing fully diluted earnings per share.


                                      F-5
<PAGE>

H.   Stock Based Compensation

     The  Company   accounts  for  stock   options   issued  to  employees   and
non-employees in accordance with the provisions of SFAS No. 123(R),  "Accounting
for Stock-Based Compensation", which requires that issuances of stock options be
recorded at fair market value.

I.   Impact of New Accounting Standards

     In March 2005, the SEC staff issued additional  guidance on SFAS 123 (R) in
the form of Staff  Accounting  Bulletin  ("SAB") No. 107.  SAB 107 was issued to
assist preparers by simplifying some of the implementation challenges of FAS 123
(R) while enhancing the information  that investors  receive.  SAB 107 creates a
framework  that is premised on two themes:  (a)  considerable  judgment  will be
required by preparers to successfully  implement FAS 123 (R),  specifically when
valuing employee stock options; and (b) reasonable  individuals,  acting in good
faith, may conclude differently on the fair value of employee share options. Key
topics covered by SAB 107 include: (a) valuation models - SAB 107 reinforces the
flexibility allowed by FAS 123 (R) to choose an option-pricing  model that meets
the standard's fair value measurement  objective;  (b) expected volatility - the
SAB provides  guidance on when it would be  appropriate  to rely  exclusively on
either historical or implied volatility in estimating expected  volatility;  and
(c) expected  term - the new  guidance  includes  examples  and some  simplified
approaches to  determining  the expected term under certain  circumstances.  The
Company will apply the principles of SAB 107 in conjunction with its adoption of
SFAS 123 (R) but does not believe its adoption will have material  impact on the
Company's financial statements or results of operations.

     In December  2004,  the FASB issued SFAS No. 153,  Exchanges of Nonmonetary
Assets,  an  amendment  of APB  Opinion  No.  29.  SFAS No.  153  addresses  the
measurement  of  exchanges  of  nonmonetary  assets and  redefines  the scope of
transactions  that  should be  measured  based on the fair  value of the  assets
exchanged.  SFAS No. 153 is effective for nonmonetary asset exchanges  occurring
in fiscal  periods  beginning  after June 15, 2005. The adoption of SFAS No. 153
did not have a material impact on the Company's financial  statements or results
of operations.

     In January 2003,  the FASB issued FASB  Interpretation  No. 46, ("FIN 46"),
Consolidation of Variable Interest Entities ("VIE").  Until this interpretation,
the Company generally included entities in its consolidated financial statements
only if it controlled the entity through voting interests. FIN No. 46 requires a
variable  interest entity,  as defined,  to be consolidated by a company if that
company is subject to a majority of the risk of loss from the variable  interest
entity's  activities or entitled to receive a majority of the entity's  residual
returns. FIN No. 46 is effective for reporting periods ending after December 15,
2003. The adoption of FIN No. 46 did not have a material impact on the Company's
Consolidated Financial Statements as of March 31, 2006.


                                      F-6
<PAGE>

     In March 2005, FASB issued FASB Interpretation  ("FIN") No. 47, "Accounting
for Conditional  Asset Retirement  Obligations."  FIN 47 clarifies that the term
"Conditional  Asset  Retirement  Obligation"  as used in FASB Statement No. 143,
"Accounting for Asset  Retirement  Obligation,"  refers to a legal obligation to
perform  an asset  retirement  activity  in which the  timing  and/or  method of
settlement  are  conditional on a future event that may or may not be within the
control  of the  entity.  Accordingly,  an entity is  required  to  recognize  a
liability for the fair value of a Conditional Asset Retirement Obligation if the
fair value of the liability can be reasonably estimated.  FIN 47 is effective no
later than the end of fiscal years ending  after  December 15, 2005.  Management
does not  believe  the  adoption  of FIN 47 will have a  material  affect on the
Company's financial position,  results of operations or cash flows. In May 2005,
the  Financial   Accounting  Standards  Board  ("FASB")  issued  SFAS  No.  154,
Accounting  Changes  and Error  Corrections  ("SFAS No.  154"),  which  replaced
Accounting  Principles Board Opinion No. 20, Accounting  Changes and SFAS No. 3,
Reporting  Accounting  Changes in  Interim  Financial  Statements.  SFAS No. 154
changes the  requirements  for the  accounting  for and reporting of a change in
accounting principles.  It requires retrospective  application to prior periods'
financial  statements  of  changes  in  accounting  principles,   unless  it  is
impracticable to determine either the period-specific  effects or the cumulative
effect of the change.  This  statement is effective for  accounting  changes and
corrections  of errors made in fiscal years  beginning  after December 15, 2005.
The  impact  on the  Company's  operations  will  depend  on  future  accounting
pronouncements or changes in accounting principles.

     In November 2004, the Financial  Accounting  Statements Board (FASB) issued
SFAS Statement No. 151,  "Inventory Costs," an amendment of Accounting  Research
Bulletin  ("ARB") No. 43,  Chapter 4. Under FASB Statement No. 151, all abnormal
amounts of idle facility expense,  freight, handling costs, and wasted materials
(spoilage)  should be  recognized  as  current-period  charges by requiring  the
allocation  of fixed  production  overheads  to  inventory  based on the  normal
capacity of the production facilities. The adoption of this pronouncement is not
expected  to have a  material  impact  on the  Company's  financial  statements,
results of operations, or cash flows.

     In May 2005, the Financial  Accounting Standards Board ("FASB") issued SFAS
No.  154,  Accounting  Changes and Error  Corrections  ("SFAS No.  154"),  which
replaces Accounting Principles Board Opinion No. 20, Accounting Changes and SFAS
No. 3, Reporting  Accounting Changes in Interim Financial  Statements.  SFAS No.
154 changes the requirements for the accounting for and reporting of a change in
accounting principles.  It requires retrospective  application to prior periods'
financial  statements  of  changes  in  accounting  principles,   unless  it  is
impracticable to determine either the period-specific  effects or the cumulative
effect of the change.  This  statement is effective for  accounting  changes and
corrections  of errors made in fiscal years  beginning  after December 15, 2005.


                                      F-7
<PAGE>

The  impact  on the  Company's  operations  will  depend  on  future  accounting
pronouncements or changes in accounting principles.

J.   Off-Balance Sheet Arrangements

     The Company does not have any off-balance  sheet credit exposure related to
its customers.

NOTE 3  GOING CONCERN

     The Company's financial statements are prepared using accounting principles
generally accepted in the United States of America applicable to a going concern
that  contemplates  the  realization of assets and liquidation of liabilities in
the normal  course of business.  The Company has not  established  any source of
revenue to cover its  operating  costs.  The Company will engage in very limited
activities  without  incurring  any  liabilities  that must be satisfied in cash
until  a  source  of  funding  is  secured.   The  Company  will  offer  noncash
consideration  and seek equity lines as a means of financing its operations.  If
the Company is unable to obtain revenue  producing  contracts or financing or if
the revenue or financing it does obtain is  insufficient  to cover any operating
losses it may incur, it may substantially curtail or terminate its operations or
seek other business  opportunities through strategic alliances,  acquisitions or
other arrangements that may dilute the interests of existing stockholders.

NOTE 4  SHAREHOLDER'S EQUITY

     On July 27, 2004 (inception),  the Board of Directors issued 148,000 shares
of common stock for $148 in services to the founding  shareholder of the Company
to fund organizational start-up costs.

     On February 23, 2005, the Board of Directors  issued  11,500,000  shares of
common stock for $11,500 in services  rendered to an officer and director of the
Company.

Common Stock

     The holders of the Company's common stock:

     * Have equal ratable rights to dividends  from funds legally  available for
payment of dividends when, as and if declared by the board of directors;

     * Are  entitled  to  share  ratably  in  all of the  assets  available  for
distribution to holders of common stock upon liquidation, dissolution or winding
up of our affairs;

     * Do not have preemptive,  subscription or conversion rights, or redemption
or access to any sinking fund; and


                                      F-8
<PAGE>

     * Are  entitled  to one  non-cumulative  vote  per  share  on  all  matters
submitted to stockholders for a vote at any meeting of stockholders.

Preferred Stock

     The Company has authorized,  but not issued, 20,000,000 shares of preferred
stock at $.001 per share.  The board of directors has the authority to establish
and fix the  designation,  powers,  or preferences  of preferred  shares without
further vote by the shareholders.

NOTE 5  SUBSEQUENT EVENTS

     On May 8, 2006,  an agreement and plan of  reorganization  was entered into
among the Company;  Asia Biotechnology Group Inc., a corporation organized under
the laws of British Virgin Islands (the "ABG"); Far Grand Investments Limited, a
corporation  organized  under  the  laws  of  Cayman  Islands,   acting  as  the
shareholder  of ABG,  (the "ABG  Shareholder");  Harbin OT  Pharmaceutical  Co.,
Limited,  a company  organized  under the laws of Samoa  (the "OT  Samoa");  and
shareholders of OT Samoa ( collectively the "OT Samoa Shareholders").

     The  respective  Boards of Directors of the Company,  ABG and OT Samoa have
adopted  resolutions  pursuant to which all of the issued and outstanding shares
of the  common  stock  of ABG  (the  "ABG  Share")  and  all of the  issued  and
outstanding  shares of OT Samoa (the "OT Samoa  Shares") will be converted  into
the right to receive a  specified  number of shares of the  common  stock of the
Company (the " Shares"); and whereas, the sole consideration for the exchange of
the ABG Share shall be the receipt by the ABG Shareholder of 23,296,000  Shares,
$0.001 par value per share; and the sole  consideration  for the exchange of the
OT Samoa Shares shall be the receipt by the OT Samoa  Shareholders of 23,296,000
Shares, $0.001 par value per share.

     The ABG Shareholder and the OT Samoa  Shareholders  individually  agrees to
transfer  to the  Company at the closing  (the  "Closing")  the ABG Share and OT
Samoa Shares, in exchange for newly issued and restricted shares of common stock
of the Company.  In connection  with the acquisition of the ABG Share and the OT
Samoa  Shares,  the Company shall issue to the ABG  Shareholder  an aggregate of
Twenty Three  Million Two Hundred and Ninety Six Thousand  (23,296,000)  Shares,
and shall  simultaneously  issue to the OT Samoa  Shareholders  an  aggregate of
Twenty Three Million Two Hundred and Ninety Six Thousand  (23,296,000) shares of
the Company common stock.  Such shares at the Closing shall equal eighty percent
(80%) of the issued and  outstanding  shares of the Company.  After the Closing,
there will be 58,240,000  outstanding  shares of common stock of the reorganized
the Company.


                                      F-9
<PAGE>

     ABG and OT Samoa both became the Company's  wholly owned  subsidiaries  and
the former  shareholders of ABG  ("shareholders")  obtained effective  operating
control of the combined  company after the share  exchange.  Generally  accepted
accounting  principles require that ABG whose  shareholders  retain the majority
interest  in a  combined  business  be treated as the  acquirer  for  accounting
purpose,  resulting in a reverse  acquisition.  Accordingly,  the share exchange
transaction  has been accounted for as a  recapitalization  of the Company.  The
equity section of future  financial  statements  will be restated to reflect the
recapitalization  of the Company due to the reverse  acquisition as of the first
day of the first period presented.

























                                      F-10
<PAGE>

Item 2. Management's Discussion and Analysis or Plan of Operation

DISCLAIMER REGARDING FORWARD LOOKING STATEMENTS

Certain  statements  in this Form 10-QSB which are not  statements of historical
fact are what are known as  "forward-looking  statements,"  which are  basically
statements about the future. For that reason,  these statements involve risk and
uncertainty  since no one can  accurately  predict  the  future.  Words  such as
"plans,"  "intends," "hopes," "seeks,"  "anticipates,"  "expects," and the like,
often identify such forward looking statements,  but are not the only indication
that a statement is a forward-looking statement. Such forward-looking statements
include  statements  concerning  our plans and  objectives  with  respect to our
present and future  operations,  and statements which express or imply that such
present and future operations will or may produce  revenues,  income or profits.
These and other factors may cause our actual results to differ  materially  from
any  forward-looking  statement.  We caution you not to place undue  reliance on
these  forward-looking  statements.   Although  we  base  these  forward-looking
statements  on our  expectations,  assumptions,  and  projections  about  future
events,  actual events and results may differ materially,  and our expectations,
assumptions,  and  projections may prove to be inaccurate.  The  forward-looking
statements  speak only as of the date  hereof,  and we  expressly  disclaim  any
obligation   to  publicly   release  the  results  of  any  revisions  to  these
forward-looking  statements to reflect events or circumstances after the date of
this filing.

BACKGROUND OF THE COMPANY

The Company was organized  under the Laws of the State of Delaware,  on July 27,
2004, as a blank check or shell company whose primary  purpose is to engage in a
merger with,  or  acquisition  of one or a small number of private  firms.  Such
firms  are   expected  to  be  private   corporations,   partnerships   or  sole
proprietorships.  From inception  through the present time, the primary activity
of the Company has been  directed  towards  organizational  efforts,  compliance
matters and locating potential merger candidates.  The Company is still a "blank
check" or "shell" company.

GENERAL OVERVIEW

The Company's  activities  since  inception have been limited to  organizational
matters,  compliance efforts and locating  potential merger candidates,  and the
Company has not engaged in any operating activity since its inception.

The  Company  has  registered  its  Common  Stock on a Form  10-SB  registration
statement  filed pursuant to the  Securities  Exchange Act of 1934 (the Exchange
Act) and Rule 12(g) thereof.  The Company files with the Securities and Exchange
Commission  periodic  reports  under Rule 13(a) of the Exchange  Act,  including
quarterly reports on Form 10-QSB and annual reports on Form 10-KSB.


                                       1
<PAGE>

The  Company  was  formed  to  engage  in a  merger  with or  acquisition  of an
unidentified  foreign or  domestic  private  company  which  desires to become a
reporting  (public)  company whose  securities  are qualified for trading in the
United States  secondary  market.  The Company  meets the  definition of a blank
check company  contained in Section  7(b)(3) of the  Securities  Act of 1933, as
amended.

Management  believes  that there are  perceived  benefits  to being a  reporting
company with a class of  publicly-traded  securities  which may be attractive to
foreign and domestic private companies.

These benefits are commonly thought to include (1) the ability to use registered
securities to make acquisition of assets or businesses; (2) increased visibility
in the financial  community;  (3) the  facilitation  of borrowing from financial
institutions;  (4) improved trading efficiency;  (5) shareholder liquidity;  (6)
greater ease in subsequently  raising capital; (7) compensation of key employees
through  options  for stock for which  there is a public  market;  (8)  enhanced
corporate image; and, (9) a presence in the United States capital market.

A private  company which may be interested  in a business  combination  with the
Company may include (1) a Company for which a primary purpose of becoming public
is the use of its securities for the acquisition of assets or businesses;  (2) a
company which is unable to find an underwriter of its securities or is unable to
find an underwriter of securities on terms acceptable to it; (3) a company which
wishes to become  public with less dilution of its Common Stock than would occur
normally upon an underwriting; (4) a company which believes that it will be able
to obtain investment capital on more favorable terms after it has become public;
(5) a foreign  company  which may wish an initial  entry into the United  States
securities market; (6) a special situation company,  such as a company seeking a
public  market to satisfy  redemption  requirements  under a qualified  Employee
Stock Option Plan;  and, (7) a company seeking one or more of the other benefits
believed to attach to a public company.

The  Company is  authorized  to enter into a  definitive  agreement  with a wide
variety  of  private  businesses  without  limitation  as to their  industry  or
revenues. It is not possible at this time to predict with which private company,
if any, the Company  will enter into a definitive  agreement or what will be the
industry, operating history, revenues, future prospects or other characteristics
of that company.

As of the date hereof, management has not made any final decision for a business
combination with any private corporations, partnerships or sole proprietorships.
When any such  agreement is reached or other  material fact occurs,  the Company
will file notice of such  agreement  or fact with the  Securities  and  Exchange


                                       2
<PAGE>

Commission on Form 8-K.  Persons  reading this Form 10-QSB are advised to see if
the Company has subsequently filed a Form 8-K.

There is no trading market for our common stock and no market may ever exist for
the  Company's  common  stock.  The Company  plans to assist  broker-dealers  in
complying with Rule 15c2-11 of the Securities  Exchange Act of 1934, as amended,
so  that  such   brokers   can  trade  the   Company's   common   stock  in  the
Over-The-Counter Electronic Bulletin Board (the "OTC Bulletin Board"). There can
be no assurance to  investors  that any  broker-dealer  will  actually  file the
materials required in order for such OTC Bulletin Board trading to proceed.

The  Securities  and  Exchange  Commission  has  adopted a rule (Rule 419) which
defines a blank-check  company as (i) a development stage company,  that is (ii)
offering penny stock, as defined by Rule 3a51-1,  and (iii) that has no specific
business plan or purpose or has indicated  that its business plan is engage in a
merger or acquisition with an unidentified company or companies.

BUSINESS COMBINATION

The Company will attempt to locate and negotiate with a business  entity for the
combination  of that target  company  with the  Company.  The  combination  will
normally take the form of a merger, stock-for-stock exchange or stock-for-assets
exchange (the "business combination"). In most instances the target company will
wish to structure  the business  combination  to be within the  definition  of a
tax-free reorganization under Section 351 or Section 368 of the Internal Revenue
Code of 1986, as amended.  No  assurances  can be given that the Company will be
successful in locating or negotiating with any target business.

The Company has not  restricted  its search for any specific kind of businesses,
and it may acquire a business which is in its preliminary or development  stage,
which is already in operation, or in essentially any stage of its business life.
It is  impossible to predict the status of any business in which the Company may
become engaged, in that such business may need to seek additional  capital,  may
desire  to  have  its  shares  publicly  traded,  or may  seek  other  perceived
advantages which the Company may offer.

In implementing a structure for a particular business  acquisition,  the Company
may become a party to a merger, consolidation, reorganization, joint venture, or
licensing agreement with another corporation or entity.

It is anticipated  that any securities  issued in any such business  combination
would be issued in reliance upon exemption from  registration  under  applicable
federal  and  state  securities  laws.  In  some  circumstances,  however,  as a
negotiated element of its transaction,  the Company may agree to register all or
a part of such securities immediately after the transaction is consummated or at


                                       3
<PAGE>

specified times thereafter.  If such registration  occurs, it will be undertaken
by the  surviving  entity after the Company has entered into an agreement  for a
business combination or has consummated a business combination.  The issuance of
additional securities and their potential sale into any trading market which may
develop  in the  Company's  securities  may  depress  the  market  value  of the
Company's securities in the future if such a market develops,  of which there is
no assurance.

The  Company  will  participate  in  a  business   combination  only  after  the
negotiation and execution of appropriate agreements.  Negotiations with a target
company  will likely  focus on the  percentage  of the Company  which the target
company shareholders would acquire in exchange for their shareholdings. Although
the terms of such agreements cannot be predicted, generally such agreements will
require  certain  representations  and warranties of the parties  thereto,  will
specify  certain  events of  default,  will  detail the terms of closing and the
conditions  which  must be  satisfied  by the  parties  prior to and after  such
closing and will include  miscellaneous  other terms.  Any merger or acquisition
effected by the Company can be expected to have a significant dilutive effect on
the percentage of shares held by the Company's shareholders at such time.

OPERATIONAL RESULTS

The Company has no current  operating  history and does not have any revenues or
earnings from operations.  The Company has no assets or financial resources.  We
will,  in all  likelihood,  sustain  operating  expenses  without  corresponding
revenues,  at least until the consummation of a business  combination.  This may
result  in the  Company  incurring  a net  operating  loss  that  will  increase
continuously  until the Company can  consummate  a business  combination  with a
profitable business opportunity. There is no assurance that we can identify such
a business opportunity and consummate such a business combination.

We are dependent  upon our officers to meet any de minimis costs that may occur.
William Tay, an officer and  director of the Company,  has agreed to provide the
necessary funds, without interest, for the Company to comply with the Securities
Exchange Act of 1934, as amended; provided that he is an officer and director of
the Company when the obligation is incurred. All advances are interest-free.

LIQUIDITY

At March 31,  2006 and  March 31,  2005,  the  Company  had no cash and no other
assets.

OFF-BALANCE SHEET ARRANGEMENTS

We do not have any off-balance  sheet  arrangements  that have or are reasonably
likely to have a current or future effect on our financial condition, changes in


                                       4
<PAGE>

financial  condition,  revenues or expenses,  results of operations,  liquidity,
capital expenditures or capital resources that is material to investors.

GOING CONCERN

The  financial  statements  included  in  this  filing  have  been  prepared  in
conformity with generally  accepted  accounting  principles that contemplate the
continuance of us as a going concern.  Our lack of cash is inadequate to pay all
of  the  costs  associated  with  our  operations.  Management  intends  to  use
borrowings  and  security  sales to mitigate  the effects of its cash  position,
however no  assurance  can be given that debt or equity  financing,  if and when
required  will  be  available.  The  financial  statements  do not  include  any
adjustments relating to the recoverability and classification of recorded assets
and classification of liabilities that might be necessary should we be unable to
continue existence.

SUBSEQUENT EVENTS

     On May 8, 2006,  an agreement and plan of  reorganization  was entered into
among the Company;  Asia Biotechnology Group Inc., a corporation organized under
the laws of British Virgin Islands (the "ABG"); Far Grand Investments Limited, a
corporation  organized  under  the  laws  of  Cayman  Islands,   acting  as  the
shareholder  of ABG,  (the "ABG  Shareholder");  Harbin OT  Pharmaceutical  Co.,
Limited,  a company  organized  under the laws of Samoa  (the "OT  Samoa");  and
shareholders of OT Samoa ( collectively the "OT Samoa Shareholders").

     The  respective  Boards of Directors of the Company,  ABG and OT Samoa have
adopted  resolutions  pursuant to which all of the issued and outstanding shares
of the  common  stock  of ABG  (the  "ABG  Share")  and  all of the  issued  and
outstanding  shares of OT Samoa (the "OT Samoa  Shares") will be converted  into
the right to receive a  specified  number of shares of the  common  stock of the
Company (the " Shares"); and whereas, the sole consideration for the exchange of
the ABG Share shall be the receipt by the ABG Shareholder of 23,296,000  Shares,
$0.001 par value per share; and the sole  consideration  for the exchange of the
OT Samoa Shares shall be the receipt by the OT Samoa  Shareholders of 23,296,000
Shares, $0.001 par value per share.

     The ABG Shareholder and the OT Samoa  Shareholders  individually  agrees to
transfer  to the  Company at the closing  (the  "Closing")  the ABG Share and OT
Samoa Shares, in exchange for newly issued and restricted shares of common stock
of the Company.  In connection  with the acquisition of the ABG Share and the OT
Samoa  Shares,  the Company shall issue to the ABG  Shareholder  an aggregate of
Twenty Three  Million Two Hundred and Ninety Six Thousand  (23,296,000)  Shares,
and shall  simultaneously  issue to the OT Samoa  Shareholders  an  aggregate of
Twenty Three Million Two Hundred and Ninety Six Thousand  (23,296,000) shares of
the Company common stock.  Such shares at the Closing shall equal eighty percent


                                       5
<PAGE>

(80%) of the issued and  outstanding  shares of the Company.  After the Closing,
there will be 58,240,000  outstanding  shares of common stock of the reorganized
the Company.

     ABG and OT Samoa both became the Company's  wholly owned  subsidiaries  and
the former  shareholders of ABG  ("shareholders")  obtained effective  operating
control of the combined  company after the share  exchange.  Generally  accepted
accounting  principles require that ABG whose  shareholders  retain the majority
interest  in a  combined  business  be treated as the  acquirer  for  accounting
purpose,  resulting in a reverse  acquisition.  Accordingly,  the share exchange
transaction  has been accounted for as a  recapitalization  of the Company.  The
equity section of future  financial  statements  will be restated to reflect the
recapitalization  of the Company due to the reverse  acquisition as of the first
day of the first period presented.

ITEM 3. Controls and Procedures

On January 17, 2006, Coast To Coast Financial  International,  Inc., a US Virgin
Islands Corporation acquired 11,500,000  restricted common shares of the Company
in a private  purchase  transaction.  On January  19,  2006,  Wang Hui  acquired
11,065,600 shares from Coast To Coast Financial International, Inc. in a private
purchase  transaction.  Wang Hui became the  "control  person" of the Company as
that term is defined in the Securities  Act of 1933, as amended.  Simultaneously
with this transaction,  the Board of Directors of the Company nominated Wang Hui
to the Board of Directors and all former officers and directors  resigned.  Wang
Hui was then named President, Secretary and Treasurer of the Company.

Based on this most recent evaluation,  which was completed within 90 days of the
filing of this Form 10-QSB,  the Company's  president  and  principal  financial
officer believe the Company's  disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) are  effective to ensure that  information
required  to be  disclosed  by the  Company in this  report is  accumulated  and
communicated  to the  Company's  management,  as  appropriate,  to allow  timely
decisions regarding required disclosure.

                          PART II -- OTHER INFORMATION

Item 1. Legal Proceedings.

There are no legal proceedings against the Company and the Company is unaware of
such proceedings contemplated against it.

Item 2. Changes in Securities.

On January 17, 2006, Coast To Coast Financial  International,  Inc., a US Virgin
Islands Corporation acquired 11,500,000  restricted common shares of the Company
in a private  purchase  transaction.  On January  19,  2006,  Wang Hui  acquired


                                       6
<PAGE>

11,065,600 shares from Coast To Coast Financial International, Inc. in a private
purchase  transaction.  Wang Hui became the  "control  person" of the Company as
that term is defined in the Securities Act of 1933, as amended.

Item 3. Defaults upon Senior Securities.

Not applicable.

Item 4. Submission of Matters to a Vote of Security Holders.

Not applicable.

Item 5. Other Information.

Not applicable.

Item 6. Exhibits and Reports on Form 8-K.

     1)   Exhibits

31.1 - Certification of Chief Executive Officer pursuant to Rule 13a-14 and Rule
15d-14(a) of the Exchange Act.

31.2 - Certification of Chief Financial Officer pursuant to Rule 13a-14 and Rule
15d-14(a) of the Exchange Act.

32.1 -Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2 -  Certification  of the  Chief  Financial  Officer  pursuant  to 18 U.S.C.
Section 1350, as adopted  pursuant to Section 906 of the  Sarbanes-Oxley  Act of
2002.

     2)   Reports on Form 8-K

          A Form 8-K was filed on April 13,  2006 by the  Company to reflect the
          change of control.





                                       7
<PAGE>

                                   SIGNATURES

In accordance with the  requirements of the Exchange Act, the Registrant  caused
this  report to be  signed on its  behalf  by the  undersigned,  thereunto  duly
authorized.


ASIA BIOTECHNOLOGY GROUP INC.


Dated: September 30, 2006
By: /s/ Xueliang Qiu
    President and CEO




















                                       8